Design and study of peptide-based inhibitors of amylin cytotoxicity.


The incidence of type II diabetes is on the increase each year and the World Health Organisation (WHO) predicts there to be over 360 million diabetic patients worldwide by the year 2030. Deposits consisting mainly of a small protein, called islet amyloid polypeptide (amylin), which aggregates into oligo-/polymeric beta sheet structures is responsible for… (More)
DOI: 10.1016/j.bmcl.2010.01.004


3 Figures and Tables

Cite this paper

@article{Muthusamy2010DesignAS, title={Design and study of peptide-based inhibitors of amylin cytotoxicity.}, author={K Rajeshwari Muthusamy and Per I Arvidsson and Patrick Govender and Hendrik G. Kruger and Glenn E. M. Maguire and Thavendran Govender}, journal={Bioorganic & medicinal chemistry letters}, year={2010}, volume={20 4}, pages={1360-2} }